Intra-Cellular Therapies Inc. (ITCI) financial statements (2021 and earlier)

Company profile

Business Address 430 EAST 29TH STREET
NEW YORK, NY 10016
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments108554643844756135
Cash and cash equivalents108553849476135
Short-term investments  427335428  
Receivables   0000
Prepaid expense 2     
Other undisclosed current assets123298548703
Total current assets:23035546938848313138
Noncurrent Assets
Operating lease, right-of-use asset18
Property, plant and equipment2111100
Other noncurrent assets0000000
Deferred tax assets, net11    
Other undisclosed noncurrent assets0      
Total noncurrent assets:21221100
TOTAL ASSETS:25135747138948413138
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities231685333
Accounts payable71464223
Employee-related liabilities1522111 
Debt3      
Other undisclosed current liabilities102065383
Total current liabilities:363614116117
Noncurrent Liabilities
Long-term debt and lease obligation20      
Operating lease, liability20
Liabilities, other than long-term debt 3332  
Deferred revenue and credits332  
Deferred rent credit 3
Total noncurrent liabilities:203332  
Total liabilities:563917138117
Stockholders' equity
Stockholders' equity attributable to parent, including:19531845437647612132
Common stock0000000
Common stock, value, subscriptions     0
Additional paid in capital90588186268567020989
Accumulated other comprehensive income (loss)0(1)(1)(0)(1)(0) 
Accumulated deficit(710)(562)(407)(309)(193)(88)(58)
Other undisclosed stockholders' equity attributable to parent     (0) 
Total stockholders' equity:19531845437647612132
TOTAL LIABILITIES AND EQUITY:25135747138948413138

Income statement (P&L) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
Revenue, net00013
Gross profit:0 00013
Operating expenses(154)(162)(103)(119)(106)(42)(35)
Other undisclosed operating income     106
Operating loss:(154)(162)(103)(118)(106)(31)(26)
Nonoperating income
(Investment Income, Nonoperating)
6743100
Interest and debt expense   (0) (0)(1)
Loss from continuing operations before income taxes:(148)(155)(99)(115)(105)(31)(27)
Income tax expense (benefit)(0)(0)1(1)(0)(0)(0)
Net loss available to common stockholders, diluted:(148)(155)(98)(116)(105)(31)(27)

Comprehensive Income ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
Net loss:(148)(155)(98)(116)(105)(31)(27)
Other comprehensive income (loss)10(0)0(0)(0) 
Comprehensive loss, net of tax, attributable to parent:(147)(155)(98)(116)(105)(31)(27)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: